C hemotherapy may offer effective palliation in the management of metastatic breast cancer (MBC). Anthracyclinefbased regimens are still considered a standard therapy for MBC. However, the increasing use of anthracyclines during the adjuvant setf f ting necessitates the search for novel combinations to eff f fectively treat patients who develop metastatic disease.
Vinorelbine administered intravenously generates a consistent level of activity, with overall response rates ranging from 35% to 50% and a highly acceptable toxicf f ity profile. 1f8 Capecitabine is an oral fluoropyrimidine that preferentially delivers fluorouracil to the tumor. 
BACKGROUND AND OBJECTIVES:
Vinorelbine and capecitabine are both active in breast cancer with moderate toxicity. DESIGN AND SETTING: a pilot study conducted from december 2007 to January 2010 in patients with metastatic breast cancer (mbc) to the evaluate efficacy and safety of combination therapy with vinorelbine and capecitabine. PATIENTS AND METHODS: the study included patients with mbc who were previously treated by anthracyclines either during the adjuvant phase or the metastatic phase. patients were treated with oral vinorelbine (60 mg/m 2 ) on day 1+8 and capecitabine (1000 mg/m 2 ) twice daily (Vc) from day 1 to day 14 with both repeated every 3 weeks until progression, refusal or for a maximum of 8 cycles. a dose reduction was made in case of grade 3 and 4 toxicities. RESULTS: of 31 women (median age, 51 years), 12 cases were first-line therapy and 19 cases were second-line therapy or greater, and 30 were evaluable for response. two patients (6.4%) achieved complete response and 15 patients (48.4%) had a partial response giving an overall response rate of 54.8% (95% ci, 42%-68%). time-todisease progression was 7.8 months for patients receiving Vc as first-line therapy versus 6 months for patients receiving Vc as second-line therapy or more, while median survival time was 22 months and 10 months for the two groups, respectively. CONCLUSIONS: the oral Vc regimen is effective and safe in patients with mbc previously exposed to anthracy--clines, and offers a promising alternative to the intravenous route. its role as a salvage therapy following anthracy--cline failure or as first-line chemotherapy requires further study.
objective response rates of 20% to 36%, and a median survival of more than 1 year. 9f14 The therapeutic activity of the combination of fluof f rouracil with vinorelbine in MBC has already been tested by other investigators in six phase II studies. In two studies, fluorouracil was administered in bolus, 15f16 whereas in the other four studies, it was administered as a continuous infusion over 3 to 5 days.
17f20 Overall, the combination achieved high response rates (up to 70% as firstfline approach), but tolerance was not satisfactory (grade 3/4 leukopenia was observed in a high percentf f age [20% to 90%] of cases).
Considering the efficacy of the combination of 5fFU and vinorelbine, in the previous studies and the substif f tution of 5fFU (with or without leucovorin) by the oral administration of capecitabine may provide a convef f nient alternative in the treatment of advanced breast cancer. 13 In fact, the greater acceptability of oral versus intravenous agents in this clinical setting has been firmf f ly established. 21 The potential advantages of oral chef f motherapy agents, which include ease of administraf f tion and reduced need for hospitalization, are likely to provide a useful contribution to improvement of care, as long as an equivalent level of efficacy is maintained.
The combination of vinorelbine and capecitabine (VC) may have some potential benefits, as the two drugs have different mechanisms of action and resisf f tance with a rather nonfoverlapping toxicity profile. 22 The presence of synergy between the two drugs on some cancer cell lines had been reported. 23 The aim of this pilot study was to evaluate the efficacy and toxicf f ity of VC regimen in patients with MBC previously exposed to anthracyclines.
PATIENTS AND METHODS
Thirtyfone patients with MBC were included in this study that was conducted from August 2007 to January 2010. Eligibility criteria included histologically (or cyf f tologically) confirmed breast cancer with at least one measurable metastatic site. All patients had to be previf f ously treated by an anthracyclinefbased regimen (doxof f rubicin or epirubicin) during either the adjuvant or the metastatic phase of the disease. Eligibility criteria also entailed an Eastern Cooperative Oncology Group (ECOG) performance status ≤2 and a definite failure of hormonal therapy in hormone receptor (+ve) paf f tients. In addition, patients had to have a platelet count ≥100 000/mm 3 , hemoglobin ≥10/dL, and an absolute neutrophil count >1500/mm 3 , with adequate cardiac, renal and hepatic function. Informed consent was obf f tained in all patients. Patients with overexpressed Herf 2 receptors and CNS metastatic disease at the time of enrollment were excluded from the study.
Patients were considered to be anthracycline ref f sistant if they had disease progression during prior anthracyclinefbased treatment, whether in metastatic or adjuvant phase (primary resistant), or those who progressed within 3 months of completing anthracyf f clinefbased treatment for metastatic disease or within 6 months of completing anthracyclinefbased treatment during adjuvant phase (secondary resistant). Otherwise, patients were considered to be anthracycline sensitive.
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Pretreatment assessment included medical history (with all the details of prior treatment), physical exf f amination, CBC/platelet, routine biochemical profile including a CA15f3 assay. Metastatic workup included isotopic bone scan, CT of the chest, abdomen and pelf f vis. Any other images were done when appropriately indicated. Clinical examination, blood count, liver enf f zymes, serum creatinine and CA15f3 were performed on a 3 weekly basis, while baseline radiological images were performed following the third and sixth cycles of chemotherapy, at the end of the treatment course, and every 3 months during follow up.
The VC regimen consisted of oral vinorelbine (60 25 while toxicity was assessed according to the National Cancer Institute Common Toxicity Criteria (NCIfCTC; version 3.0). 26 Treatment was continued for a maximum of 8 cycles, provided there was no disease progression or the patient refused. The primary objective of this study was to assess the efficacy of this combination by determining overall ref f sponse rate. Secondary endpoints were the assessment of the toxicity of the VC regimen as well as the timef tofdisease progression and the survival at one year.
Time to disease progression was calculated from the date of first treatment course to the date of docuf f mented disease progression. Survival was the interval between the date of the start of treatment and the date of death. If a patient was lost to followfup, that patient was censored as of the date of last contact.
The descriptive analysis was done using an IBM compatible computer and Statistics 6.0 for Windows XP statistical package. Overall survival was estimated by the Kaplan Meier method. Comparison of survival curves was done by Log Rank test.
RESULTS
The characteristics of the 31 included patients are listed in Table 1 . The majority of patients (71%) had visceral metastasis, while 68% had 2 or more metaf f static sites. Performance status (PS) according to the ECOG score was 0f1 in 53% and 2 in 47%. All patients received a prior anthracyclinefbased regimen during eif f ther the adjuvant phase (61%) or metastatic phase of the disease (39%). Twelve patients (39%) were considf f ered anthracycline resistant. The median time from last anthracycline treatment to inclusion in the study was 7 months. Nineteen cases (61%) had received the study regimen as a secondf or thirdfline treatment for their metastatic disease. During the study period, a total of 159 cycles were administered with a median of 6 cycles per patient. In 42 cycles (26%) there was 25% dose ref f duction of the two drugs. A delay of treatment with both drugs not more than 4 days occurred in 22% of the cycles.
Common grade 3f4 toxicities observed were hand and foot syndrome in 7 patients (22.5%), neutropenia in 5 patients (16%) with 2 of the latter (6.4%) develf f oping febrile neutropenia. Other grade 3f 4 toxicities included thrombocytopenia (9.6%), anemia (6.4%), diarrhea in (12.9%), vomiting (3.2%), oral mucositis (3.2%) and fatigue in (6.4%). Toxicity was more obf f served in patients that received VC as secondf or thirdf line therapy (Table 2) .
Among the 31 included patients, 30 were considf f ered valuable for response as one patient refused to continue treatment after she received the first week of treatment due to grade 3 vomiting. The overall ref f sponse rate (intent to treat) was 54.8% (95% CI: 42%f 68%). Two patients (6.4%) achieved complete response (CR), 15 cases (48.4%) achieved partial response (PR), with a median duration of response of 10.5 months. Six cases (19%) had disease stability, with control of the disease in 74% while 8 cases (26%) progressed on treatment (Table 3) . Among the 12 cases who received the VC regimen as firstfline therapy, 8 cases (67%) had an objective response versus 9 (47%) in the 19 patients receiving their treatment as secondfline or greater therapy (no CR were seen in the latter group). The response rate was also superior in anthracyclinefsensitive patients (63%) compared to those with anthracycline resistance (42%).
The median timeftofprogression for the 12 patients who received the VC combination as firstfline therapy was 7.8 months compared to 6 months among the 19 patients who received the combination as a secondf or thirdfline therapy. The 19 patients who were anthraf f cycline sensitive had 7.8 months median timeftofprof f gression compared to 6 months in the 12 patients who were anthracycline resistant. The median survival time for the whole group was 13 months with a range of 2 to 43 months and the actuarial onefyear survival was 53% (Figure 1) . The median survival time for the 12 patients who received the VC combination as firstf line was 21 months with a range of 4 to 43+ months compared to 10 months (range, 2f21 months) among those who received the combination as secondf or thirdfline. The median survival time was 17 months among patients who were anthracycline sensitive verf f sus 10 months among those who were resistant to anf f thracycline. Patients who were anthracyclinefsensitive showed 1f and 2fyear actuarial overall survival of 56% and 21%, respectively, compared to 42% and 9% for those who were anthracycline resistant.
DISCUSSION
In chemotherapyfnaive patients anthracyclinef and/or taxanefbased regimens have significant efficacy. It is important to note that the widespread use of anthraf f cyclines and taxanes in the adjuvant setting has led to an increasing number of patients presenting with adf f vanced disease that is resistant to both drugs. In this population, treatment options remain controversial bef f cause no standard chemotherapy has been defined, and there is a need for the testing of new effective regimens with a favorable therapeutic index. Patients who have progressive disease during or immediately after adjuf f vant anthracycline treatment have a poor prognosis and a small chance of achieving an objective response when treated with other cytotoxic agents.
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The present study comprised a relatively small numf f ber of patients with MBC whose pretreatment charf f acteristics seemed to be predictive of a less favorable outcome. Among them, two or more previous chemof f therapy lines and visceral metastases have been clearly shown to be related to a poor outcome. 27 The only faf f vorable prognostic parameter was the relatively good performance status. In this setting, the VC combinaf f tion showed considerable activity, with an overall ref f sponse rate of 54.8% and a CR rate of 6.4%. Responses were seen in soft tissue and visceral sites, as well as in patients with one site or more sites involvement. It is well known that the extent of previous therapies will usually influence the results of the protocol treatf f ment. Accordingly, this study yielded a higher overall response rate (67%) in patients who received the VC regimen as firstfline, versus 42% in those receiving their treatment as secondfline or higher therapy (no CR were seen in the latter group). However, the more than 40% response rate obtained in the latter cases was noteworthy, because it seemed to be higher than exf f pected in a heavily pretreated patient population.
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The responses achieved were durable. The median survival time for the 12 patients who received VC comf f bination as firstfline line was 21 months with (range, 4f43+) compared to 10 months (range, 2f21 months) among those who received the combination as secondf or thirdfline therapy. The latter finding was unexpectf f edly high, considering the poor prognosis and the chef f moresistance of the patients enrolled. The relatively good performance status of the enrolled patients and the long duration of the responses obtained may have been both contributory. However, this result must be confirmed in large randomized trials.
As expected the efficacy data in our study demf f onstrated inferior results in anthracyclinefresistant compared to anthracyclinefsensitive patients, but the small sample size of our study does not allow for a relif f able subgroup analysis. The results of the study clearly showed that the combination regimen seems to be non-crossfresistant to anthracyclines and represents a valid option to be tested in randomized studies for patients with primary resistance to anthracyclines in an adjuvant setting or in metastatic disease or in paf f tients with progressive disease after discontinuation of anthracyclinefbased chemotherapy.
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The non-crossfresistance of vinorelbine with respect to anthracyclines has been reported repeatf f edly. 29, 30 However, it is unlikely that oral vinorelbine alone can yield such results, because its reported acf f tivity in anthracyclinefresistant patients has not exf f ceeded 30%. 29, 31 Similarly, the response rate obtained with capecitabine as a secondf or thirdfline approach in metastatic breast cancer was 20% to 33%. 13, 14 Therefore, the high response rate of oral vinorelbine and capecitabine in the present study was probably due to in vivo synergism between the two drugs rather than an overlapping effect.
It is noteworthy that the high therapeutic activity of the capecitabine and vinorelbine combination has already been described by other investigators, 32f34 with almost comparable efficacy and safety. Nole et al 32 34 in another study using the same dose of capecitabinne and vinorelbine, reported a response rate of 56.5%, but all the patients were receiving it as firstfline therapy after failure of anf f thracycline.
The toxicity of this combination seems to be even less than that obtained in published data for the two drugs used as single agents.
6f8, 11, 12, 14 In particular, the combination regimen in our study resulted in mild hef f matologic toxicity, because grade 3/4 neutropenia was found in only 16% of cases, compared with 20% to 49% reported in others studies. 32f35 The low dosefintensity adopted for each drug and the absence of an overlapf f ping toxicity profile could account for the better tolerf f ability of this regimen.
In summary, the oral VC regimen is an effective and safe regimen in MBC patients previously exposed to anthracyclines, and offers a promising alternative to the intravenous route. Its role as a salvage therapy followf f ing anthracycline failure or as firstfline chemotherapy requires further large or randomized studies.
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